IDIOPATHIC INFLAMMATORY MYOPATHY
Clinical trials for IDIOPATHIC INFLAMMATORY MYOPATHY explained in plain language.
Never miss a new study
Get alerted when new IDIOPATHIC INFLAMMATORY MYOPATHY trials appear
Sign up with your email to follow new studies for IDIOPATHIC INFLAMMATORY MYOPATHY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Engineered immune cells target Hard-to-Treat autoimmune diseases in groundbreaking trial
Disease control Recruiting nowThis early-stage study is testing a new CAR T-cell therapy for people with severe autoimmune diseases like lupus, rheumatoid arthritis, and scleroderma that haven't responded to standard treatments. Researchers will collect immune cells from participants, genetically modify them …
Matched conditions: IDIOPATHIC INFLAMMATORY MYOPATHY
Phase: PHASE1 • Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company • Aim: Disease control
Last updated Apr 04, 2026 03:36 UTC
-
One-Shot cell therapy aims to reset immune system in devastating muscle diseases
Disease control Recruiting nowThis study is testing a single dose of an experimental cell therapy called CABA-201 for adults and children with active autoimmune muscle diseases, like dermatomyositis. The therapy uses the patient's own modified immune cells (CAR T-cells) to target and remove harmful B cells th…
Matched conditions: IDIOPATHIC INFLAMMATORY MYOPATHY
Phase: PHASE2, PHASE3 • Sponsor: Cabaletta Bio • Aim: Disease control
Last updated Apr 04, 2026 03:36 UTC
-
Scientists test 'Living Drug' to reset the immune system in lupus and related diseases
Disease control Recruiting nowThis is a first-in-human study testing the safety and early effectiveness of a new type of cell therapy called ALLO-329 in adults with severe autoimmune diseases like lupus, myositis, and scleroderma. The therapy involves giving patients specially engineered immune cells (CAR T c…
Matched conditions: IDIOPATHIC INFLAMMATORY MYOPATHY
Phase: PHASE1 • Sponsor: Allogene Therapeutics • Aim: Disease control
Last updated Mar 27, 2026 12:40 UTC